In a significant leap forward for interventional cardiology and pulmonary medicine, Pulnovo Medical has officially commenced patient enrollment for its pivotal PULSE-LHD investigational device exemption (IDE) trial in the United States. This clinical study marks a critical milestone in the evaluation of pulmonary artery denervation (PADN)—a minimally invasive therapeutic approach aimed at addressing the complex physiological challenges of pulmonary hypertension (PH) associated with left heart disease.
The first two patients have been successfully treated at the Henry Ford Hospital in Detroit, signalling the beginning of what the medical community hopes will be a transformative journey in managing patients with WHO Group 2 pulmonary hypertension.
Main Facts: The PULSE-LHD Trial
The PULSE-LHD trial is a multi-centre, randomised, placebo-procedure controlled clinical investigation designed to establish the safety and clinical efficacy of the PADN system. The primary focus of this study is patients diagnosed with combined pre- and post-capillary pulmonary hypertension associated with left heart disease (CpcPH-LHD).
Unlike traditional pharmacological treatments that often struggle to address the underlying sympathetic nervous system hyperactivity associated with PH-LHD, PADN utilizes a specialized multi-pole radiofrequency (RF) ablation catheter. By modulating the sympathetic nerve activity within the pulmonary arteries, the procedure aims to inhibit vascular remodelling and slow the progression of the disease.
The trial is being conducted under a US Food and Drug Administration (FDA) IDE, which allows the investigational device to be used in a clinical study to collect safety and effectiveness data. The procedures at Henry Ford Hospital were led by site principal investigator Dr. Waleed Al-Darzi, alongside Drs. Vikas Aggarwal and Brian O’Neill, marking a high-profile entry into the US clinical landscape for the Chinese-headquartered medical technology firm.
A Chronology of Progress: From Pilot Studies to Global Expansion
The journey of Pulnovo Medical’s PADN technology has been marked by a rapid evolution from initial pilot studies to robust global clinical investigation.
- Initial Development and Early Adoption: Having established a footprint in the treatment of WHO Group 1 pulmonary hypertension, Pulnovo secured regulatory approvals in 12 countries and regions. To date, the company estimates that approximately 1,500 PADN procedures have been performed globally outside the United States.
- Regional Growth (2025–2026): Throughout 2026, the company aggressively expanded its footprint, receiving regulatory clearances for its RF ablation catheter and generator in Indonesia, Malaysia, and the Baltic States, further cementing its position as a global leader in this niche field.
- The PADN-Columbus Milestone: At the EuroPCR 2026 conference, data from the PADN-Columbus pilot study were presented. These results provided early safety signals and encouraging improvements in pulmonary haemodynamics and patient functional capacity, setting the stage for more rigorous testing.
- Strategic Capital Injection: In April 2026, the company announced the successful closure of a $100 million strategic financing round. This round, led by medical device giant Medtronic, provided the necessary liquidity and strategic backing to accelerate the US-based PULSE-LHD trial.
- Current Status: With the treatment of the first US patients, the company is now fully operational within the American clinical research ecosystem, with plans to present further data from the PADN-HF-PH registration trial in China at the upcoming ESC Congress 2026.
Supporting Data and the Scientific Rationale
The scientific premise behind PADN rests on the role of the sympathetic nervous system in cardiovascular pathology. In patients with PH-LHD, the pulmonary vasculature often undergoes structural remodelling, a process significantly exacerbated by excessive sympathetic nerve activity.
The PADN procedure uses radiofrequency energy to disrupt these nerve pathways, theoretically reducing pulmonary vascular resistance and improving cardiac function. While the 2022 ESC/ERS (European Society of Cardiology/European Respiratory Society) guidelines classified PADN as an investigational therapy—noting a current gap in definitive evidence—the ongoing trials are specifically designed to fill this void.
It is important to note, however, that while studies outside the US have shown positive associations with functional capacity in Group 1 PH patients, these findings are not inherently predictive of outcomes in the PULSE-LHD study. The complexity of Group 2 PH (left heart disease) presents a different biological profile, making the current US-based, placebo-controlled study essential for regulatory approval.
Official Perspectives: Leadership and Vision
The initiation of the PULSE-LHD trial is a personal and professional victory for the leadership at Pulnovo Medical. Jessie Lian, Executive Director and CEO of Pulnovo Medical, emphasized the strategic importance of the trial during the announcement.
"Bringing innovative technologies to the global stage requires a deep understanding of local clinical practices and a commitment to tackling implementation challenges head-on," Lian stated. "Achieving this milestone alongside our frontline teams perfectly exemplifies our exceptional execution in multi-centre collaboration."
Lian further highlighted that the partnership with top-tier institutions, such as Henry Ford Hospital, is a deliberate strategy to ensure the clinical evidence base is of the "highest quality standards." She added, "We are dedicated not only to addressing the immense unmet clinical needs in Group 2 pulmonary hypertension but also to bringing renewed hope for health to a broader population of heart failure and pulmonary hypertension patients worldwide."
The involvement of Dr. Waleed Al-Darzi and his team at Henry Ford Hospital underscores the confidence that major US medical institutions have in the potential of this technology. By participating in an FDA-regulated IDE trial, these clinicians are at the forefront of what could become a new standard of care for a notoriously difficult-to-treat patient population.
Implications for the Future of Cardiology
The implications of the PULSE-LHD trial are far-reaching. If the study successfully meets its endpoints, it could fundamentally alter the treatment paradigm for pulmonary hypertension associated with left heart disease—a condition for which current therapeutic options are often limited to managing symptoms or addressing the underlying heart failure through medication.
1. Addressing an Unmet Clinical Need
Patients with CpcPH-LHD currently face a poor prognosis and a reduced quality of life. Traditional vasodilators used for other forms of PH have often failed or shown detrimental effects in Group 2 patients. PADN represents a novel, non-pharmacological approach that could offer a breakthrough for patients who have exhausted conventional treatment avenues.
2. Validation of Minimally Invasive Therapies
The success of PADN would validate the shift toward device-based modulation of the autonomic nervous system in cardiology. This follows a broader trend in the medical device industry, where targeted interventional procedures are increasingly viewed as complements or alternatives to chronic systemic drug therapy.
3. Market and Investment Impact
The backing of Medtronic, the world’s largest medical device company, in the recent $100 million financing round suggests that the industry sees significant market potential in PADN. The ability of Pulnovo to navigate the regulatory landscapes of 12 countries while simultaneously initiating a rigorous US IDE study positions them as a formidable player in the interventional cardiology space.
4. A Template for Global Clinical Research
The PULSE-LHD trial serves as a blueprint for how international medical technology companies can integrate into the US regulatory environment. By partnering with established academic and clinical institutions and adhering to strict, randomized, placebo-controlled protocols, Pulnovo is demonstrating the discipline required to gain acceptance from global regulatory bodies like the FDA and the EMA.
Conclusion
As the PULSE-LHD trial gains momentum, the global medical community will be watching closely. While it is too early to declare PADN a definitive success for all PH-LHD patients, the methodical approach taken by Pulnovo Medical, coupled with the rigorous oversight of the FDA, ensures that the data generated will be instrumental in defining the future of this therapy.
For the patients currently enrolled and those who may follow, this trial offers more than just participation in a study; it offers the prospect of a new, targeted intervention for a condition that has long lacked sufficient treatment options. With the PADN-HF-PH registration data expected at the ESC Congress 2026 and the ongoing progress at US sites, the next eighteen months promise to be a pivotal chapter in the history of pulmonary hypertension management.
About the Author
